Subscribe to our newsletter

Kevin Doxzen

Kevin received his PhD in biophysics from the lab of Jennifer Doudna at the University of California Berkeley. He is a Hoffmann Fellow joint between Thunderbird School of Global Management, Sandra Day O'Connor College of Law at Arizona State University, and the World Economic Forum's Center for the Fourth Industrial Revolution. Kevin's research focuses on policy and governance challenges in precision medicine and healthcare, including equitable access to gene therapies and other breakthrough technologies.

Follow Kevin:

From This Author

Rapid DNA Sequencing Tech Breaks the Speed Record for Reading Whole Genomes

-
For children suffering from rare diseases, it usually takes years to receive a diagnosis. This “diagnostic odyssey” is filled with multiple referrals and a barrage of tests, seeking to uncover the root cause behind...
Read more

Gene Therapies Are Almost Here, But Healthcare Isn’t Ready for Sky-High Prices

-
Zolgensma—which treats spinal muscular atrophy, a rare genetic disease that damages nerve cells, leading to muscle decay—is currently the most expensive drug in the world. A one-time treatment of the life-saving drug for a...
Read more

Singularity University, Singularity Hub, Singularity Summit, SU Labs, Singularity Labs, Exponential Medicine, Exponential Finance and all associated logos and design elements are trademarks and/or service marks of Singularity Education Group.

© 2022 Singularity Education Group. All Rights Reserved.

Singularity University is not a degree granting institution.